34,276 results match your criteria Lymphoma Lymphoblastic


Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.

Indian J Hematol Blood Transfus 2020 Jul 2;36(3):498-504. Epub 2020 Jan 2.

Department of Community Medicine, Lady Hardinge Medical College, New Delhi, India.

Methotrexate (MTX) forms the backbone of maintenance cycles in childhood acute lymphoblastic leukemia (ALL) chemotherapy, including interim maintenance. There is sufficient published data describing toxicities of high dose MTX (HD-MTX), but toxicities with escalating doses of MTX (Capizzi regimen) is not well documented. Capizzi regimen is thought to be relatively safe; we contend that even low escalating doses of MTX have significant toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-019-01245-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326748PMC

Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.

Clin Lymphoma Myeloma Leuk 2020 Jun 3. Epub 2020 Jun 3.

Department of Medicine A - Hematology, Hemostaseology, Oncology, Pulmonology, University Hospital Münster, Münster, Germany. Electronic address:

Background: Blinatumomab and inotuzumab ozogamicin are now widely used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Patients And Methods: We have reported the clinical course of 34 adult patients with r/r B-ALL receiving blinatumomab or inotuzumab ozogamicin at our institution from 2009 to 2019.

Results: Blinatumomab-based salvage therapy was applied for overt r/r B-ALL (n = 13) or minimal residual disease (MRD) positivity (n = 5). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.022DOI Listing

Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol.

Leuk Lymphoma 2020 Jul 9:1-9. Epub 2020 Jul 9.

Department of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, China.

This study evaluated the long-term therapeutic effect and prognostic factors of acute lymphoblastic leukemia (ALL) in 100 young Chinese children (<2 years old) who were enrolled in the Shanghai Children's Medical Center (SCMC)-ALL-2009 study in five pediatric hematological disease centers based on collaboration. The 5-year and 10-year event-free survivals (EFS) were 74.7 ± 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786557DOI Listing

Aggressive lung involvement in a patient with T-acute lymphoblastic leukaemia/lymphoblastic lymphoma: a tricky and rare case report.

Respirol Case Rep 2020 Aug 2;8(6):e00614. Epub 2020 Jul 2.

Department of Respiratory Medicine Kyorin University Tokyo Japan.

A 39-year-old man was admitted to our university hospital because of diffuse pulmonary infiltrates on chest X-ray. He had been diagnosed with T-acute lymphoblastic leukaemia/lymphoblastic lymphoma three years before and had been treated with chemotherapy and cord blood stem cell transplantation twice. Although he had neither blast cells in the peripheral blood nor leucocytosis, urgent bronchoscopy findings demonstrated blast cells invading both the alveolar spaces/alveolar septa and the vein walls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcr2.614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330916PMC

Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.

Clin Lymphoma Myeloma Leuk 2020 May 21. Epub 2020 May 21.

Department of Oncology, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.

Background: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). Adult patients fit for pediatric-inspired protocols have an excellent outcome with chemotherapy alone. However, it is unclear whether patients receiving hyper-CVAD should undergo allogeneic hematopoietic cell transplantation (HCT) as postremission therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.012DOI Listing

T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.

Br J Haematol 2020 Jul 7. Epub 2020 Jul 7.

Vanderbilt University Medical Centre, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16929DOI Listing

Primary cauda equina T-cell lymphoblastic lymphoma.

World Neurosurg 2020 Jul 4. Epub 2020 Jul 4.

University Medical Center Groningen; Department of Neurosurgery. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2020.06.184DOI Listing

Forkhead Box C1 (FOXC1) Expression in Stromal Cells within the Microenvironment of T and NK Cell Lymphomas: Association with Tumor Dormancy and Activation.

Cancer Res Treat 2020 Jul 3. Epub 2020 Jul 3.

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Purpose: Forkhead box C1 (FOXC1) is critical for maintaining bone marrow microenvironments during hematopoiesis, but its role in hematological malignancies remains obscure. Here, we investigated whether FOXC1 regulates tumor dormancy and activation in the microenvironments of T and natural killer (NK) cell lymphomas.

Materials And Methods: One hundred and twenty cases of T and NK cell lymphomas were included; the immunohistochemical expression of FOXC1 was investigated in stromal cells, and numbers of FOXC1+ stromal cells were counted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.032DOI Listing

A case of primary cutaneous B-cell lymphoma with immature features in an old man. Diffuse Large B-cell Lymhpoma with immature features or B-cell Lymhpoblastic Lymphoma?

J Cutan Pathol 2020 Jul 4. Epub 2020 Jul 4.

Oncology and Hematology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Primary cutaneous B-cell lymphomas are a heterogeneous group of lymphoid neoplasms primarily occurring in the skin. Although most cases are represented by primary cutaneous follicle center cell lymphoma, primary cutaneous marginal zone lymphoma and leg-type diffuse large B-cell lymphoma, other diffuse large B-cell lymphomas and B-cell lymphoblastic lymphoma may rarely present primarily in the skin. In this setting, the presence of histopathologic and immunohistochemical features of cellular immaturity is exceedingly rare and may represent a diagnostic challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13795DOI Listing

Emperipolesis of lymphocytes by mesothelial cells in pleural effusion involved by T-lymphoblastic lymphoma.

Diagn Cytopathol 2020 Jul 4. Epub 2020 Jul 4.

Pathology Section, Rashid Hospital, Dubai, United Arab Emirates.

Emperipolesis is a physiologic or pathologic phenomenon characterized by the presence of intact viable cells within the cytoplasm of another cell. It has been described in normal tissues and in a variety of inflammatory and neoplastic lesions such as Rosai-Dorfman disease, tumors, hematopoietic disorders and rarely lymphomas. Emperipolesis by mesothelial cells is rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24543DOI Listing

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.

Leuk Lymphoma 2020 Jul 3:1-9. Epub 2020 Jul 3.

Comprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany.

Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE immuno-oncotherapy, 15 µg/m/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1780583DOI Listing

Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.

Cancer Sci 2020 Jul 3. Epub 2020 Jul 3.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Although next-generation sequencing-based panel testing is well-practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical-sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical-sequencing assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14552DOI Listing

B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

Onco Targets Ther 2020 18;13:5795-5805. Epub 2020 Jun 18.

Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, People's Republic of China.

Purpose: B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro experiments, the aim of this study was to explore the regulatory mechanism of B7-H6 in NHL in order to provide new therapeutic strategies that can potentially be applied in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S257512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308182PMC

B-cell maturation antigen expression across hematologic cancers: a systematic literature review.

Blood Cancer J 2020 Jun 30;10(6):73. Epub 2020 Jun 30.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0337-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327051PMC

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

BMC Cancer 2020 Jun 30;20(1):612. Epub 2020 Jun 30.

Research and Development, Adaptive Biotechnologies Corporation, 1551 Eastlake Ave. E, Suite 200, Seattle, WA, 98102, USA.

Background: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe studies to validate the analytical performance of the assay using patient samples and cell lines.

Methods: Sensitivity and specificity were established by defining the limit of detection (LoD), limit of quantitation (LoQ) and limit of blank (LoB) in genomic DNA (gDNA) from 66 patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), or chronic lymphocytic leukemia (CLL), and three cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-07077-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652PMC

Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.

Clin Lymphoma Myeloma Leuk 2020 Apr 23. Epub 2020 Apr 23.

Adult Hematology-Oncology Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Background: In adult B cell precursor acute lymphoblastic leukemia (BCP-ALL), CD20 expression has generally been associated with an adverse prognosis. Incorporating rituximab to standard of care is found to improve the outcome of CD20 BCP-ALL. The aim of this study is to estimate the prognostic effect of CD20 expression and the impact of rituximab in BCP-ALL in Saudi Arabia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.008DOI Listing

Paediatric ocular adnexal lymphoma: a population-based analysis.

BMJ Open Ophthalmol 2020 21;5(1):e000483. Epub 2020 Jun 21.

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.

Objective: To investigate the incidence, clinicopathological characteristics and survival of ocular adnexal lymphoma (OAL) in the paediatric population.

Methods And Analysis: In this retrospective case series, the Surveillance, Epidemiology and End Results database was accessed to identify individuals with OAL ≤18 years of age, diagnosed between 1973 and 2015. OAL located in the eyelid, conjunctiva, lacrimal apparatus and orbit were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjophth-2020-000483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312335PMC

Serological Evaluation of Anti- Antibodies in Patients with Acute Leukemia and Lymphoma through Chemotherapy.

Iran J Parasitol 2020 Apr-Jun;15(2):187-195

Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Background: is a protozoan parasite that belongs to the family Coccidae. We aimed to evaluate IgG avidity and the changes of anti- immunoglobulins M (IgM) and G (IgG) in patients with acute leukemia and lymphoma.

Methods: Ninety eight patients with Acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and lymphoma, selected from patients referring to Imam Reza Hospital of Tabriz (38°04'N 46°18'E), in terms of the presence of anti- IgM, IgG, IgG avidity antibodies and the major risk factors were evaluated. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311818PMC

Outcomes of T-lymphoblastic lymphoma treated with pediatric ALL-like protocol.

Indian J Cancer 2020 Jun 22. Epub 2020 Jun 22.

Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Background: The management of T-lymphoblastic lymphoma (T-LBL) in adults poses uncertainties, including optimal chemotherapy regimen, need for radiotherapy, and the benefit of stem cell transplant. This retrospective case series investigated the efficacy of the pediatric BFM-90 regimen in adult patients and evaluated the role of early response assessment by positron emission tomography with computed tomography (PET-CT) in predicting outcomes.

Methods: Patients aged 15 years or older with T-LBL diagnosed at Tata Memorial Hospital, Mumbai, India were given chemotherapy according to the European BFM-90 protocol (n = 38). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_616_18DOI Listing

Primary testicular T-lymphoblastic lymphoma in a child: A case report.

Medicine (Baltimore) 2020 Jun;99(26):e20861

Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University.

Rationale: Primary non-Hodgkin lymphoma (NHL) of the testes is rare, representing about 9% of testicular neoplasms and 1% to 2% of non-Hodgkin lymphomas.

Patient Concerns: A previously healthy 47-month-old boy came to our institution for 3 months unilateral testicular swelling without tenderness. After preliminary examination, inguinal orchiectomy was performed to resect the right scrotal mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328915PMC

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

Lancet Haematol 2020 Jul;7(7):e523-e533

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia. Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small extracellular loop of CD20 and has greater in vitro complement-mediated cytotoxicity than rituximab. In this study, we assessed the activity and safety of ofatumumab in combination with chemotherapy in patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30144-7DOI Listing

Chimeric Antigen Receptors for the Tumour Microenvironment.

Adv Exp Med Biol 2020 ;1263:117-143

Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.

Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-44518-8_8DOI Listing

Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin.

Authors:
Philip Savage

Front Genet 2020 9;11:426. Epub 2020 Jun 9.

Department of Oncology, Brighton and Sussex University Hospitals, Brighton, United Kingdom.

Cytotoxic DNA damaging chemotherapy brings clinical benefits in the treatment of many metastatic malignancies. However routine curative treatment remains restricted to a small number of malignancies including acute leukemia, high grade lymphoma, germ cell tumors, gestational malignancies and some of the rare childhood cancers. The detailed explanation for this dramatic divergence in outcomes remains to be elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2020.00426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295948PMC

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma.

J Pediatr Hematol Oncol 2020 Jul;42(5):e310-e314

Departments of Pediatric Hematology and Oncology.

The aim of this study is to evaluate the clinical and laboratory findings of pediatric patients with non-Hodgkin lymphoma (NHL) who developed Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Between 2006 and 2018, the medical records of child patients with NHL who developed SJS and TEN were reviewed retrospectively. SJS/TEN developed in 7 of 70 patients with NHL (10%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001851DOI Listing

Acute lymphoblastic leukemia mortality in Hispanic Americans.

Leuk Lymphoma 2020 Jun 22:1-8. Epub 2020 Jun 22.

Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Higher incidence and poorer outcomes of acute lymphoblastic leukemia (ALL) in Hispanic Americans have been attributed to high-risk molecular markers associated with Native American (NA) ancestry. However, the diverse Hispanic populations in the United States differ substantially in ancestry. Continental Hispanics have a high proportion of NA ancestry while Caribbean Hispanics have a lower proportion of NA ancestry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1779260DOI Listing

Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments.

Oncol Lett 2020 Jul 4;20(1):448-454. Epub 2020 May 4.

Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Zuoying, Kaohsiung 813, Taiwan, R.O.C.

B-cell acute lymphoblastic lymphoma (B-ALL) is a disease found mainly in children and in young adults. B-ALL is characterized by the rapid proliferation of poorly differentiated lymphoid progenitor cells inside the bone marrow. In the United States, ~4,000 of these patients are diagnosed each year, accounting for ~30% of childhood cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2020.11583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285861PMC

Blastic Plasmacytoid Dendritic Cell Neoplasm: Case Report and Literature Overview.

Indian J Dermatol 2020 May-Jun;65(3):217-221

Novosibirsk Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a malignancy with high frequency of skin involvement. A 39-year-old Caucasian female was suffering from weakness, myalgia, and skin eruption, which appeared during treatment of chlamydiosis with antibiotics in July 2016. Based on clinical presentation, laboratory investigations, and histological examination of skin and bone marrow biopsy, a diagnosis of BPDCN with the involvement of skin, bone marrow, and central nervous system was made. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_235_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292454PMC

Comparison of Overall Survival Between De Novo and Secondary Acute Lymphoblastic Leukemia Patients of Different Ages.

Clin Lymphoma Myeloma Leuk 2020 Apr 30. Epub 2020 Apr 30.

Department of Hematology, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, PR China.

Purpose: To compare the overall survival (OS) between de novo and secondary acute lymphoblastic leukemia (ALL) patients in different age groups after chemotherapy.

Patients And Methods: Data from 8305 ALL patients undergoing chemotherapy from the Surveillance, Epidemiology, and End Results (SEER) database during 1975 to 2015 were included in this study, of which 7454 (80.11%) were in the de novo ALL group, and 851 (19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.013DOI Listing

Parotitis due to Burkholderia cepacia Infection after Autologous Hematopoietic Stem Cell Transplantation.

Transpl Infect Dis 2020 Jun 21:e13374. Epub 2020 Jun 21.

Department of Laboratory, The First Affiliated Hospital of Wannan Medical College, Wuhu, China.

Burkholderia cepacia predominantly causes opportunistic infections in hospitalized and immunocompromised patients such as patients with cystic fibrosis, cancer, or human immunodeficiency virus (HIV). Nonetheless, Burkholderia cepacia is infrequently reported to cause infection in hematopoietic stem cell transplantation (HSCT) recipients. Herein, we report a rare case of suppurative parotitis in a 31-year-old patient with T-cell lymphoblastic lymphoma (T-LBL) who underwent auto-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13374DOI Listing

Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study.

Bone Marrow Transplant 2020 Jun 20. Epub 2020 Jun 20.

Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.

HLA haploidentical hematopoietic stem cell transplantation (HSCT), i.e., HSCT from a 1-HLA-haplotype-mismatched family donor, has been successfully performed even as a second transplantation for posttransplant relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0980-8DOI Listing

Ibrutinib is not an effective drug in primografts of TCF3-PBX1.

Transl Oncol 2020 Jun 18;13(10):100817. Epub 2020 Jun 18.

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands. Electronic address:

Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) express BTK and are sensitive to ibrutinib in vitro. However, preclinical studies in mice are lacking that justify clinical implementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2020.100817DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306596PMC

A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.

Clin Lymphoma Myeloma Leuk 2020 May 11. Epub 2020 May 11.

Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.

Introduction: CD123 is overexpressed in many hematologic malignancies and found to be useful in characterizing leukemic blasts of both acute myeloid leukemia (AML) and B-acute lymphoblastic leukemia (B-ALL). CD123 has been recently found to be a marker of leukemic stem cells, and its utility to measure residual disease and potential role in disease relapse is under evaluation.

Materials And Methods: Herein, we have evaluated the expression of CD123 in 757 samples of acute leukemia including 479 treatment-naive and 278 follow-up samples and compared with post-induction morphologic complete remission and measurable residual disease (MRD) status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.004DOI Listing

Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.

J Clin Oncol 2020 Jun 17:JCO2000531. Epub 2020 Jun 17.

Division of Blood and Marrow Transplantation, Children's National Health System, Washington, DC.

Purpose: The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multi-agent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL) and gained preliminary data using nelarabine in high-risk patients.

Patients And Methods: The trial enrolled 299 patients, age 1-31 years. High-risk (HR) patients had ≥ 1% minimal detectable disease (MDD) in the bone marrow at diagnosis or received prior steroid treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00531DOI Listing

A case of systemic precursor T-cell lymphoblastic lymphoma presenting with single tooth mobility.

SAGE Open Med Case Rep 2020 3;8:2050313X20927961. Epub 2020 Jun 3.

Department of Oral and Maxillofacial Surgery, Evangelismos General Hospital of Athens, Athens, Greece.

Lymphoblastic lymphoma, seen primarily in children or young adults, is a type of non-Hodgkin lymphoma that originates from B or T lymphocyte precursors and rarely occurs in the oral cavity. A case of systemic precursor T-cell lymphoblastic lymphoma mimicking periodontitis of a lower second molar in a 20-year-old adult is currently presented. The case was initially misdiagnosed as periodontal disease and treated with tooth extraction by a dentist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X20927961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273617PMC

Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.

Leuk Lymphoma 2020 Jun 16:1-4. Epub 2020 Jun 16.

Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1775205DOI Listing

Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.

Bone Marrow Transplant 2020 Jun 15. Epub 2020 Jun 15.

Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0962-xDOI Listing

Erythematous cutaneous macules: an uncommon, challenging presentation of T-lymphoblastic lymphoma.

Eur J Dermatol 2020 Jun 14. Epub 2020 Jun 14.

Pathology Unit, Azienda Ospedaliera S. Maria di Terni, University of Perugia, Terni.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3772DOI Listing

Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases.

Hum Pathol 2020 Jun 12. Epub 2020 Jun 12.

Departments of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Diffuse large B-cell lymphoma (DLBCL) is the most common histological transformation (HT) of follicular lymphoma (FL). Other types of HT are very rare, and their incidence, histopathology, and patient outcomes have not been sufficiently described. Here, we assessed the clinicopathological characteristics of 19 cases of non-DLBCL HT of FL in a single institution in Japan, to advance the understanding of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.06.001DOI Listing

[A pediatric-inspired regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: results from a single center].

Zhonghua Xue Ye Xue Za Zhi 2020 May;41(5):399-404

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

To investigate the efficacy of using a pediatric-inspired regimen for adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph(-)) acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) at a single center in China. Clinical data of 71 consecutive newly diagnosed AYA patients with Ph(-) ALL/LBL on a pediatric-inspired regimen in Peking Union Medical College Hospital from January 2012 to November 2018 were retrospectively analyzed. Median age at diagnosis was 20 years (range: 15-38) , and 46 patients (64. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.05.007DOI Listing

[Analysis of treatment response and prognostic factors of T-LBL patients treated with pediatric-like ALL therapy following HSCT].

Zhonghua Xue Ye Xue Za Zhi 2020 May;41(5):387-393

Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.

To discuss the effect and prognostic factors of hematopoietic stem cell transplantation (HSCT) in patients with T-lymphoblastic lymphoma (T-LBL) who have achieved complete remission (CR) and partial response (PR) after pediatric-like acute lymphoblastic leukemia (ALL) therapy. Basic information and clinical data of patients with T-LBL treated in the hematologic center of Tangdu Hospital from January 2013 to January 2017 were collected, and the patients who achieved CR/PR were included in this study and retrospectively analyzed. ①A total of 48 patients received pediatric-like ALL chemotherapy, among which 39 patients achieved CR and 9 patients achieved PR after 2 courses of induction chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.05.005DOI Listing

The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia.

Br J Clin Pharmacol 2020 Jun 13. Epub 2020 Jun 13.

Department of Physiology, McGill University, Montreal, Canada.

Despite recent advances in immunotherapies, cytotoxic chemotherapy continues to be a first-line treatment option for the majority of cancers. Unfortunately, a common side effect in patients undergoing chemotherapy treatment is neutropenia. To mitigate the risk of neutropenia and febrile neutropenia, prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) is administered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14424DOI Listing

Fine-Needle Aspiration Cytology Is an Effective Diagnostic Tool in Paediatric Patients with Mucoepidermoid Carcinoma as Secondary Neoplasm.

Acta Cytol 2020 Jun 11:1-12. Epub 2020 Jun 11.

Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Background: Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumour in paediatric population, accounting for 16% of all cases. Patients affected by a previous solid or leukaemic neoplasm during their childhood may develop a second different tumour during the follow-up. In this setting, salivary gland MEC is relatively frequent, accounting for 6% of the second neoplasms in paediatric patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508395DOI Listing

T-Cell Acute Lymphoblastic Leukemia: A Cytogenomic Update.

J Assoc Genet Technol 2020 ;46(2):59-73

The International Circle of Genetic Studies, Los Angeles, CA.

Objectives: T-cell acute lymphoblastic leukemia (T-ALL) is a pervasive hematologic malignancy that arises from developmental and genetic abnormalities manifested in lymphoblasts belonging to the T-cell lineage. Responsible for 10-15% of pediatric acute lymphoblastic leukemia (ALL) and 25% of adult ALL patients, T-ALL is characterized not only by cytomorphic features, but also by the aberrant expression of specific genes critical to T-cell development. Such changes in the genome ultimately result in mutational and developmental cascades that alter the chromosomal constitution, the process of which are used to organize T-ALL cases into different subgroups according to specific gene expression signatures. Read More

View Article

Download full-text PDF

Source
January 2020

LMO2 Expression Distinguishes T-Lymphoblastic Leukemia/Lymphoma from Indolent T-Lymphoblastic Proliferations.

Histopathology 2020 Jun 11. Epub 2020 Jun 11.

Department of Pathology, University of California San Francisco, San Francisco, CA, 94143, USA.

Aims: An indolent T-lymphoblastic proliferation (iT-LBP) is a benign, reactive expansion of immature TdT+ T-cells found in extrathymic tissues. iT-LBP can be challenging to distinguish from malignant processes, specifically T-lymphoblastic lymphoma (T-LBL), given the overlapping clinical and histologic features. Recently, it has been shown that LIM domain only 2 (LMO2) is overexpressed in T-LBL but not in reactive immature TdT+ T-cells in the thymus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14176DOI Listing

Primary Paraspinal and Spinal Epidural Non-Hodgkin Lymphoma in Childhood.

J Pediatr Hematol Oncol 2020 Jun 9. Epub 2020 Jun 9.

Department of Pediatric Oncology, Hacettepe University Faculty of Medicine.

Primary paraspinal/spinal epidural lymphoma (PPSEL) is rare in childhood. Here, we retrospectively evaluated patients with PPSEL treated in our department. We also reviewed the cases reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001858DOI Listing

Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.

J Oncol Pharm Pract 2020 Jun 9:1078155220929747. Epub 2020 Jun 9.

Department of Haematology, Son Llàtzer Hospital, Palma de Mallorca, Spain.

Introduction: Nelarabine is a purine analogue approved for the treatment of patients with T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukaemia (T-ALL) that have relapsed or are refractory to two previous chemotherapy regimens. Adverse reactions to nelarabine include neurological toxicity, the pathophysiological mechanisms of which are unknown, although the administration of intrathecal therapy at therapeutic doses given concomitantly with high-dose systemic chemotherapy that crosses the blood-brain barrier may potentiate neurotoxicity.

Case Report: We report a case of a 29-year-old woman with a diagnosis of relapsed T-ALL who developed severe myelopathy and polyneuropathy of toxic origin that led to paraplegia, upper-limb paresis, and dysautonomia after the first cycle of nelarabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155220929747DOI Listing